RxDoctor Payments Data

Tali Czarnowicki, MD

Dermatology · Miami, FLNPI 1639548845

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $2,241 of the $3,580 with a category attached, or 62.6%. Sanofi accounts for 65.1% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $2,271, more than ten times the $23 reported in 2019.

$3,580in general payments, 2019–2025

Across 18 payments — averaging $198.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$2K
  • AbbVie$892
  • Lilly USA, LLC$99
  • Regeneron Healthcare Solutions, Inc.$94
  • Pfizer$76
  • LEO Pharma Inc.$67
  • plus $23 from 1 others
$81,607in research payments, 2019–2025

Across 17 payments — averaging $4800.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$63K
  • Eli Lilly$18K

What the payments were for

  • Consulting fees$2,24163%
  • Travel & lodging$70520%
  • Food & beverage$53415%
  • Education$993%

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,580 in reported general payments places this provider in the 55th percentile of 1,147 dermatology providers in Florida.

See all dermatology providers in Florida →

Medicare billing

Part B allowed, 2024
$22,976
Medicare patients
104
Services billed
259

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast11$50,905
Clobetasol Propionate13$779
Triamcinolone Acetonide30$429
Ketoconazole25$326
Mupirocin27$157
Hydrocortisone37$153

Paid to pharmacies, not to this prescriber.

Other dermatology in Miami

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →